Sagimet Biosciences Inc. (SGMT)

USD 5.25

(-11.62%)

Market Cap (In USD)

161.04 Million

Revenue (In USD)

2 Million

Net Income (In USD)

-27.87 Million

Avg. Volume

416.06 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.39-20.71
PE
-
EPS
-
Beta Value
0.0
ISIN
US7867001049
CUSIP
786700104
CIK
1400118
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. David A. Happel
Employee Count
-
Website
https://sagimet.com
Ipo Date
2023-07-17
Details
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.